GastroAGI Logo
OverviewBlogsAbout
Trending TopicsDaily BriefConference
Topics/Upper GI Tract/Achalasia Cardia and Oesophagal Cancer: Gastroenterology | September 2026
5

Achalasia Cardia and Oesophagal Cancer: Gastroenterology | September 2026

Clinical knowledge base written and curated by GastroAGI Team from primary medical literatureLast updated September 1, 2026

Introduction:

Achalasia has long been linked to oesophagal cancer, particularly oesophagal squamous cell carcinoma (ESCC). This large Nordic study strengthens evidence that achalasia independently increases ESCC risk, while its association with oesophagal adenocarcinoma (EAC) appears largely related to GERD.

Why was this study needed?

Chronic food stasis may cause inflammation, epithelial proliferation and dysplasia, promoting ESCC.

Previous studies were small and inadequately adjusted for smoking and alcohol.

Whether achalasia independently increases EAC risk remained uncertain.

Study Design:

Using registries from five Nordic countries (1987–2023), investigators compared more than 35,000 esophageal cancer cases with 355,000 controls, accounting for smoking, alcohol and GERD.

Achalasia and Squamous Cell Carcinoma: A Strong Association

Achalasia was strongly associated with ESCC, independent of smoking and alcohol.

Achalasia → food stasis → chronic inflammation → dysplasia → ESCC

The association was stronger after myotomy or dilation, but this does not imply that treatment causes cancer; disease duration and severity may contribute.

What About Esophageal Adenocarcinoma?

The association between achalasia and EAC weakened substantially after accounting for GERD, suggesting:

Achalasia/treatment → reflux and acid exposure → potential EAC risk

Thus, a strong independent relationship with EAC is less certain.

The Key Message: ESCC and EAC Should Not Be Considered Together

ESCC: Strong association, likely related to chronic stasis and inflammation.

EAC: Weaker association, largely related to GERD.

Does This Mean Every Patient With Achalasia Needs Surveillance Endoscopy?

Not yet. The study does not establish that routine surveillance improves outcomes. However, new or progressive dysphagia, weight loss, anaemia, bleeding or unexplained symptom changes should prompt endoscopic evaluation.

Clinical Impact:

Achalasia should be recognised as an important risk condition for ESCC, and changing symptoms should not automatically be attributed to the underlying motility disorder.

Bottom Line:

Achalasia is strongly associated with ESCC, whereas its relationship with EAC appears largely mediated by GERD. Routine surveillance is not yet established, but new or changing symptoms warrant prompt investigation for oesophagal cancer.

Related Q&A

06

Long-Term PPI Use Does Not Increase Gastric Cancer Risk: BMJ | 2026

Introduction: Proton pump inhibitors (PPIs) are among the most widely prescribed medications worldwide. Concerns have persisted that long-term acid suppression, through hypochlorhydria and hypergastrinemia, might increase gastric cancer...

07

Liquid Nitrogen Spray Cryotherapy Offers Repeatable Palliation in Advanced Oesophagal Cancer: GIE | August 2026

Introduction: Dysphagia from advanced unresectable oesophagal cancer can severely impair nutrition and quality of life. Conventional palliation often relies on stenting or feeding-tube placement, both of which carry...

08

Primary Tumour Genomics May Predict Recurrence Patterns After Gastric Cancer Surgery: JAMA Surgery | August 2026

Introduction: Despite curative-intent resection, gastric cancer carries a substantial risk of recurrence, commonly through hematogenous, peritoneal, or lymphatic spread. Current postoperative surveillance is largely guided by clinicopathological factors....

09

Autoimmune Gastritis: Diagnosis and Management: Nature Reviews Gastroenterology & Hepatology | August 2026

Introduction: Autoimmune gastritis (AIG) is a chronic immune-mediated disorder targeting the gastric oxyntic mucosa, resulting in progressive atrophy and impaired absorption of vitamin B12, iron, and other micronutrients....

10

Nicotine E-Cigarettes for Smoking Cessation: JAMA | July 2026

Introduction: Cigarette smoking remains one of the leading causes of preventable death worldwide. This expert consensus statement from the Society for Research on Nicotine and Tobacco (SRNT) provides...

11

Dupilumab in Eosinophilic Gastritis: Nature Reviews Gastroenterology & Hepatology | July 2026

Introduction: Eosinophilic gastritis (EoG) is a rare chronic inflammatory disorder with limited effective treatment options and frequent dependence on corticosteroids. The phase II DEGAS trial evaluated dupilumab, an...

GastroAGI Logo

We are pioneers in clinical intelligence, dedicated to helping gastroenterologists harness the power of artificial intelligence to drive precision, efficiency, and patient growth.

For You

For StudentsFor CliniciansFor ResearchersFor Patients

Core Tools

MELD-Na ScoreChild-PughFIB-4 IndexGlasgow-BlatchfordBISAP Score

Explore

OverviewAboutCalculators
Trending Topics
Conference Briefings
Blog Insights
©GastroAGI 2026
Privacy PolicyTerms of UseMedical Disclaimer